Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

BACKGROUND: SWOG S0421 was a large randomized trial comparing docetaxel/prednisone plus placebo (DPP) to docetaxel/prednisone plus atrasentan over 12 cycles for patients with metastatic castration-resistant prostate cancer (mCRPC). The current report presents the PRO results for this trial, an impor...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Patient Rep Outcomes
Huvudupphovsmän: Unger, Joseph M., Griffin, Katherine, Donaldson, Gary W., Baranowski, Karen M., Good, Margorie J., Reburiano, Eunicia, Hussain, Maha, Monk, Paul J., Van Veldhuizen, Peter J., Carducci, Michael A., Higano, Celestia S., Lara, Primo N., Tangen, Catherine M., Quinn, David I., Wade, James L., III, Vogelzang, Nicholas J., Thompson, Ian M., Jr, Moinpour, Carol M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer International Publishing 2018
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5997724/
https://ncbi.nlm.nih.gov/pubmed/29951640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41687-018-0054-5
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk